Rockville, MD. Rise Therapeutics announced today that they have moved to an Alexandria Real Estate Equities, Inc. (ARE) facility that provides a larger, more effective lab space located in the ARE Maryland life science companies cluster. The mixed laboratory/office space leased by Rise Therapeutics is part of a state-of-the-art research support facility Class A office/lab building located in Rockville, Maryland.
With this facility, Rise Therapeutics, LLC currently makes use of 4,885 sq. ft. of private laboratory and office space which includes two separate laboratories of about 1,500 sq. ft. Approximately one third of the facility is office space with multiple offices, cubicles, and workstations laid out to comfortably staff up to about 20 individuals. The facility is located at 1405 Research Blvd., in Rockville, MD, approximately 10 miles north of the National Institute of Health (NIH) and 20 miles west of the Food & Drug Administration (FDA) campus in White Oak, yielding close support and connection within the ARE life science companies cluster.
“We've been considering this move for some time now. We needed the additional space to support corporate growth. The new facility provides us with a state-of-the-art laboratory facility that can accommodate our expansion into GMP manufacturing for microbiome-based cellular therapies” stated Dr. Fanger, CEO and President of Rise Therapeutics. “We are excited to move forward in this exciting direction with Alexandria Real Estate Equities and look forward to using this new space to support our development of first-in-class oral immune therapeutics.”
About Rise Therapeutics
Rise Therapeutics is a privately held biotechnology company located in Rockville, Maryland. Rise is pioneering synthetic biology methodologies to develop novel microbiome-based cellular medicines. Rise Therapeutics leverages its unique and proprietary TriPartite X (TPX) approach to deliver targeted biologics orally, a novel step forward in the context of protein-based medicines. As a platform drug delivery approach, TPX is ideally suited to deliver any biological therapy orally and, in the context of Rise’s therapeutics product development interests, targeting immunology of the gut is a key breakthrough that gives Rise a competitive drug development advantage. Rise is currently focused on developing treatments for autoimmunity, inflammatory disease, infection, and cancer. These disease areas represent a large unmet need, both in the United States and around the world. For more information about Rise Therapeutics, please visit www.risetherapeutics.com.